Aptus Pharma Limited Reports NIL Deviation in Utilization of ₹13.02 Crore IPO Proceeds for Half Year Ended March 31, 2026
Published on: May 6, 2026, 11:53 p.m. | Source: scanx.trade
Aptus Pharma Limited has submitted its Monitoring Agency Report for the half year and year ended March 31, 2026, confirming NIL deviation in the utilization of its ₹13.02 crore IPO proceeds. CARE Ratings Limited, acting as the Monitoring Agency, verified that all funds were fully deployed during H2FY26 across capital expenditure (₹1.63 crore), working capital (₹8.00 crore), general corporate purposes (₹1.91 crore), and offer expenses (₹1.48 crore), with zero unutilized balance. All objects were completed by March 2026 as scheduled, with no delays or deviations recorded. The company's share price stood at ₹360 as on April 24, 2026, against an issue price of ₹70 per share.
